Non-lipid genetic predictors of the development of coronary heart disease and myocardial infarction in patients with hypertension

Abstract

The associations between the main non-lipid genomic biomarkers and coronary heart disease occurrence and the unstable course of the disease with the development of myocardial infarction in 164 patients with stage I–III hypertension were investigated. The study was conducted in two stages. At the first stage, the non-lipid genetic predictors of coronary heart disease were determined without considering the characteristics of its clinical course. At the second stage, the possibility of identifying genetic predictors of the complicated course of coronary heart disease with the development of myocardial infarction was studied. In hypothesis testing, the difference was considered significant at p 0.05. It was found that the presence of coronary heart disease in patients with hypertension was associated with a significant predominance of genetic biomarkers in four single-nucleotide polymorphisms: in the hemostasis system (4G4G SERPINE 1), pro-inflammatory cytokines (T allele IL-1b-511, C allele IL-1b-1473), and innate immunity (FF TLR3-412). The development of myocardial infarction was associated with two genetic polymorphisms: pro-inflammatory cytokine system (CC IL-6-174) and hemostasis (4G4G SERPINE 1). In general, among the single-nucleotide polymorphisms studied, statistically significant results in predicting coronary heart disease were demonstrated by genetic biomarkers of the hemostatic system, pro-inflammatory cytokines, and innate immunity. In relation to myocardial infarction, genetic biomarkers of the hemostatic system and pro-inflammatory cytokines may have prognostic value. The use of genetic biomarker data as unfavorable prognosis predictors in patients with hypertension enables better risk stratification and assessment of the prognosis in these patients, which will significantly reduce the costs of conducting a genome-wide study.